Description of Eli Lilly's Business Segments

Eli Lilly and Company is a global leader in the pharmaceutical industry, providing a diverse range of products and services across multiple therapeutic segments. Below is a detailed overview of the company’s primary segments, products, and services:

1. Neuroscience
Eli Lillys neuroscience division is central to its portfolio, featuring a range of medications designed to address mental health and neurological disorders:

- Zyprexa® (olanzapine): An antipsychotic medication used for the treatment of schizophrenia, acute manic episodes of bipolar disorder, and maintenance therapy for bipolar disorder.
- Prozac® (fluoxetine): An antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class, indicated for major depressive disorder, bulimia nervosa, and obsessive-compulsive disorder (OCD).
- Strattera® (atomoxetine): A non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD), approved for use in children, adolescents, and adults.
- Permax® (pergolide): Primarily used in the management of Parkinsons disease to alleviate symptoms associated with the disorder.
- Sarafem® (fluoxetine): Specifically indicated for the treatment of premenstrual dysphoric disorder (PMDD), leveraging the same active ingredient as Prozac.
- Symbyax®: A combination of olanzapine and fluoxetine, this medication is indicated for treatment-resistant depression and bipolar depression.
- Darvon®: A line of analgesic products aimed at providing pain relief, primarily for mild to moderate discomfort.

Endocrine
Eli Lilly has a robust portfolio catering to diabetes management, growth hormone deficiencies, and bone health:

- Humulin®: A series of human insulin products synthesized through recombinant DNA technology, featuring various formulations for blood glucose management in diabetes.
- Humalog® (insulin lispro): A rapid-acting insulin analog designed for effective diabetes management, particularly for controlling postprandial blood glucose levels.
- Actos® (pioglitazone): Co-promoted with Takeda, this medication is used to treat Type 2 diabetes and is part of the thiazolidinedione drug class.
- Evista® (raloxifene): A selective estrogen receptor modulator (SERM) indicated for the prevention and treatment of osteoporosis in post-menopausal women.
- Humatrope® (somatropin): A synthetic growth hormone used for treating growth hormone deficiency in children and adults.
- Forteo® (teriparatide): A biologically active form of parathyroid hormone used for osteoporosis management in men and post-menopausal women at high risk for fractures.

Oncology
Eli Lillys oncology pipeline features several innovative therapies aimed at treating various cancer types:

- Gemzar® (gemcitabine): Utilized in the treatment of pancreatic cancer and for combination therapy in non-small-cell lung cancer.
- Alimta® (pemetrexed): Effective against malignant pleural mesothelioma and non-small-cell lung cancer, known for its specific action against tumors.

Animal Health
Eli Lilly extends its expertise into animal health, providing vital products for livestock and poultry management:

- Tylan® (tylosin): An antibiotic used to treat specific diseases affecting cattle, swine, and poultry.
- Rumensin® (monensin): A feed additive that enhances feed efficiency in cattle and helps control coccidiosis.
- Coban®, Monteban®, and Maxiban®: These anticoccidial agents are effective in controlling coccidiosis in poultry.
- Micotil® (tilmicosin) and Pulmotil® (tylosin): Used for managing respiratory conditions in cattle and swine, respectively.
- Paylean® and Optaflexx®: Performance enhancers designed to improve leanness and growth rates in swine and cattle.

Cardiovascular Agents
Eli Lilly is committed to addressing cardiovascular diseases with a range of medications:

- ReoPro® (abciximab): A monoclonal antibody used as an antiplatelet agent indicated for use during percutaneous coronary intervention (PCI).
- Xigris® (drotrecogin alfa): A recombinant protein indicated for the treatment of severe sepsis in critically ill patients.
- Dobutrex® (dobutamine): Utilized in managing cardiac decompensation by enhancing cardiac output.
- Cynt®: An antihypertensive medication marketed outside the U.S. for managing high blood pressure.

Anti-Infectives
Eli Lillys anti-infective line includes a variety of medications targeting bacterial infections:

- Ceclor® (cefaclor), Keflex® (cephalexin), Keftab® (cephradine), and Lorabid® (loracarbef): A range of oral antibiotics effective against various bacterial infections.
- Vancocin® HCl (vancomycin): Indicated for severe staphylococcal infections, particularly effective against MRSA.

Other Pharmaceuticals
The portfolio includes various additional therapeutic agents across different health areas:

- Axid® (nizatidine): An anti-ulcer medication used for gastric and duodenal ulcers.
- Cialis® (tadalafil): Indicated for erectile dysfunction, marketed in collaboration with ICOS Corporation, this product has achieved substantial global sales.

Research and Development
Eli Lilly is deeply committed to research and development, focusing on advancing existing medications, exploring new drug candidates across all therapeutic areas, and investigating innovative treatment strategies. Continuous investment in R&D aims to discover novel therapies that can address unmet medical needs.

Digital Health Solutions
In recognizing the increasing role of technology in healthcare, Eli Lilly is emphasizing digital health solutions. This includes the development of mobile health applications and platforms designed to enhance patient adherence to therapies, support disease management, and improve overall health outcomes for patients.

This extensive portfolio demonstrates Eli Lilly and Companys dedication to addressing crucial medical needs across various therapeutic segments and its ongoing commitment to innovation in the pharmaceutical industry.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Eli Lilly And Company Revenues by Segments


Net product revenue	93.2 %	of total Revenue
Collaboration and other revenue	6.8 %	of total Revenue
U S Sales returns rebates and discounts	0 %	of total Revenue
U S	61.21 %	of total Revenue
Outside U S	38.79 %	of total Revenue
Cardiometabolic Health	79.6 %	of total Revenue
Cardiometabolic Health U S	50.12 %	of total Revenue
Cardiometabolic Health Outside U S	29.48 %	of total Revenue
Mounjaro	43.75 %	of total Revenue
Mounjaro U S	21.37 %	of total Revenue
Mounjaro Outside U S	22.37 %	of total Revenue
Zepbound	21.01 %	of total Revenue
Zepbound U S	20.88 %	of total Revenue
Zepbound Outside U S	0.13 %	of total Revenue
Jardiance	5.63 %	of total Revenue
Jardiance U S	2.59 %	of total Revenue
Jardiance Outside U S	3.04 %	of total Revenue
Trulicity	4.64 %	of total Revenue
Trulicity U S	3.03 %	of total Revenue
Trulicity Outside U S	1.61 %	of total Revenue
Other cardiometabolic health	4.57 %	of total Revenue
Other cardiometabolic health U S	2.25 %	of total Revenue
Other cardiometabolic health Outside U S	2.32 %	of total Revenue
Oncology	11.46 %	of total Revenue
Oncology U S	6.2 %	of total Revenue
Oncology Outside U S	5.25 %	of total Revenue
Verzenio	6.58 %	of total Revenue
Verzenio U S	3.57 %	of total Revenue
Verzenio Outside U S	3.01 %	of total Revenue
Other oncology	4.88 %	of total Revenue
Other oncology U S	2.64 %	of total Revenue
Other oncology Outside U S	2.24 %	of total Revenue
Immunology	6.08 %	of total Revenue
Immunology U S	3.13 %	of total Revenue
Immunology Outside U S	2.95 %	of total Revenue
Taltz	3.7 %	of total Revenue
Taltz U S	2.11 %	of total Revenue
Taltz Outside U S	1.59 %	of total Revenue
Other immunology	2.37 %	of total Revenue
Other immunology U S	1.02 %	of total Revenue
Other immunology Outside U S	1.36 %	of total Revenue
Neuroscience	1.93 %	of total Revenue
Neuroscience U S	1.48 %	of total Revenue
Neuroscience Outside U S	0.45 %	of total Revenue
Other	0.94 %	of total Revenue
Other U S	0.28 %	of total Revenue
Other Outside U S	0.66 %	of total Revenue
Europe	18.42 %	of total Revenue
China	3.5 %	of total Revenue
Japan	2.88 %	of total Revenue
Rest of world	14 %	of total Revenue
Reportable Segment	100 %	of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
Net product revenue	18,453.00	93.2 %
Collaboration and other revenue	1,346.00	6.8 %
U S Sales returns rebates and discounts	0.00	0 %
U S	12,119.00	61.21 %
Outside U S	7,680.00	38.79 %
Cardiometabolic Health	15,760.00	79.6 %
Cardiometabolic Health U S	9,924.00	50.12 %
Cardiometabolic Health Outside U S	5,836.00	29.48 %
Mounjaro	8,662.00	43.75 %
Mounjaro U S	4,232.00	21.37 %
Mounjaro Outside U S	4,430.00	22.37 %
Zepbound	4,160.00	21.01 %
Zepbound U S	4,134.00	20.88 %
Zepbound Outside U S	26.00	0.13 %
Jardiance	1,114.00	5.63 %
Jardiance U S	512.00	2.59 %
Jardiance Outside U S	602.00	3.04 %
Trulicity	919.00	4.64 %
Trulicity U S	600.00	3.03 %
Trulicity Outside U S	318.00	1.61 %
Other cardiometabolic health	905.00	4.57 %
Other cardiometabolic health U S	446.00	2.25 %
Other cardiometabolic health Outside U S	460.00	2.32 %
Oncology	2,268.00	11.46 %
Oncology U S	1,228.00	6.2 %
Oncology Outside U S	1,040.00	5.25 %
Verzenio	1,302.00	6.58 %
Verzenio U S	706.00	3.57 %
Verzenio Outside U S	596.00	3.01 %
Other oncology	966.00	4.88 %
Other oncology U S	522.00	2.64 %
Other oncology Outside U S	444.00	2.24 %
Immunology	1,203.00	6.08 %
Immunology U S	619.00	3.13 %
Immunology Outside U S	584.00	2.95 %
Taltz	733.00	3.7 %
Taltz U S	417.00	2.11 %
Taltz Outside U S	315.00	1.59 %
Other immunology	470.00	2.37 %
Other immunology U S	202.00	1.02 %
Other immunology Outside U S	269.00	1.36 %
Neuroscience	382.00	1.93 %
Neuroscience U S	293.00	1.48 %
Neuroscience Outside U S	89.00	0.45 %
Other	187.00	0.94 %
Other U S	56.00	0.28 %
Other Outside U S	130.00	0.66 %
Europe	3,646.00	18.42 %
China	693.00	3.5 %
Japan	571.00	2.88 %
Rest of world	2,771.00	14 %
Reportable Segment	19,799.00	100 %
Total	19,799.00	100 %

Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
Net product revenue	59.06 %	-
Collaboration and other revenue	19.43 %	-
U S Sales returns rebates and discounts	200 %	-
U S	42.76 %	-
Outside U S	81.17 %	-
Cardiometabolic Health	71.16 %	-
Cardiometabolic Health U S	50.89 %	-
Cardiometabolic Health Outside U S	121.82 %	-
Mounjaro	125.46 %	-
Mounjaro U S	59.34 %	-
Mounjaro Outside U S	273.52 %	-
Zepbound	79.93 %	-
Zepbound U S	79.35 %	-
Zepbound Outside U S	271.43 %	-
Jardiance	9.86 %	-
Jardiance U S	65.16 %	-
Jardiance Outside U S	-14.61 %	-
Trulicity	-16.07 %	-
Trulicity U S	-22.18 %	-
Trulicity Outside U S	-2.15 %	-
Other cardiometabolic health	-4.23 %	-
Other cardiometabolic health U S	-16.64 %	-
Other cardiometabolic health Outside U S	12.2 %	-
Oncology	16.43 %	-
Oncology U S	17.4 %	-
Oncology Outside U S	15.3 %	-
Verzenio	12.34 %	-
Verzenio U S	7.29 %	-
Verzenio Outside U S	18.96 %	-
Other oncology	22.43 %	-
Other oncology U S	34.54 %	-
Other oncology Outside U S	11 %	-
Immunology	10.57 %	-
Immunology U S	7.09 %	-
Immunology Outside U S	14.51 %	-
Taltz	-3.81 %	-
Taltz U S	-12.58 %	-
Taltz Outside U S	10.53 %	-
Other immunology	44.17 %	-
Other immunology U S	98.04 %	-
Other immunology Outside U S	19.56 %	-
Neuroscience	40.44 %	-
Neuroscience U S	55.03 %	-
Neuroscience Outside U S	7.23 %	-
Other	-12.21 %	-
Other U S	-44 %	-
Other Outside U S	15.04 %	-
Europe	52.62 %	-
China	53.66 %	-
Japan	42.04 %	-
Rest of world	177.93 %	-
Reportable Segment	55.54 %	-
Total	55.55 %	-

Q1 three months ended (Mar 31 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Reportable Segment	7,396.00	37.36 %
Total	7,396.00	37.36 %

Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Reportable Segment	168.07 %	-
Total	168.04 %	-

Annual Report on Eli Lilly And Company Divisions, Sales by Country


Net product revenue	93.52 %	of total Revenue
Collaboration and other revenue	6.48 %	of total Revenue
U S Sales returns rebates and discounts	0 %	of total Revenue
U S	66.71 %	of total Revenue
Outside U S	33.29 %	of total Revenue
Cardiometabolic Health U S	51.96 %	of total Revenue
Cardiometabolic Health Outside U S	22.03 %	of total Revenue
Mounjaro U S	20.94 %	of total Revenue
Mounjaro Outside U S	14.29 %	of total Revenue
Zepbound U S	20.69 %	of total Revenue
Zepbound Outside U S	0.09 %	of total Revenue
Jardiance	5.27 %	of total Revenue
Jardiance U S	2.43 %	of total Revenue
Jardiance Outside U S	2.84 %	of total Revenue
Trulicity U S	4.47 %	of total Revenue
Trulicity Outside U S	2.09 %	of total Revenue
Other cardiometabolic health U S	3.43 %	of total Revenue
Other cardiometabolic health Outside U S	2.72 %	of total Revenue
Oncology U S	8.21 %	of total Revenue
Oncology Outside U S	6.17 %	of total Revenue
Verzenio U S	5.31 %	of total Revenue
Verzenio Outside U S	3.47 %	of total Revenue
Other oncology U S	2.9 %	of total Revenue
Other oncology Outside U S	2.71 %	of total Revenue
Immunology U S	4.55 %	of total Revenue
Immunology Outside U S	3.5 %	of total Revenue
Taltz U S	3.58 %	of total Revenue
Taltz Outside U S	1.89 %	of total Revenue
Other immunology U S	0.97 %	of total Revenue
Other immunology Outside U S	1.62 %	of total Revenue
Neuroscience U S	1.53 %	of total Revenue
Neuroscience Outside U S	0.6 %	of total Revenue
Other U S	0.47 %	of total Revenue
Other Outside U S	0.98 %	of total Revenue
Europe	17.73 %	of total Revenue
China	2.99 %	of total Revenue
Japan	3.27 %	of total Revenue
Rest of world	9.29 %	of total Revenue
Reportable Segment	100 %	of total Revenue

Twelve months ended 2025
LLY s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Net product revenue	60,958.00	93.52 %
Collaboration and other revenue	4,221.00	6.48 %
U S Sales returns rebates and discounts	0.00	0 %
U S	43,481.00	66.71 %
Outside U S	21,698.00	33.29 %
Cardiometabolic Health U S	33,864.00	51.96 %
Cardiometabolic Health Outside U S	14,357.00	22.03 %
Mounjaro U S	13,651.00	20.94 %
Mounjaro Outside U S	9,315.00	14.29 %
Zepbound U S	13,484.00	20.69 %
Zepbound Outside U S	58.00	0.09 %
Jardiance	3,432.00	5.27 %
Jardiance U S	1,582.00	2.43 %
Jardiance Outside U S	1,849.00	2.84 %
Trulicity U S	2,914.00	4.47 %
Trulicity Outside U S	1,362.00	2.09 %
Other cardiometabolic health U S	2,233.00	3.43 %
Other cardiometabolic health Outside U S	1,773.00	2.72 %
Oncology U S	5,352.00	8.21 %
Oncology Outside U S	4,024.00	6.17 %
Verzenio U S	3,464.00	5.31 %
Verzenio Outside U S	2,259.00	3.47 %
Other oncology U S	1,888.00	2.9 %
Other oncology Outside U S	1,765.00	2.71 %
Immunology U S	2,964.00	4.55 %
Immunology Outside U S	2,283.00	3.5 %
Taltz U S	2,333.00	3.58 %
Taltz Outside U S	1,230.00	1.89 %
Other immunology U S	631.00	0.97 %
Other immunology Outside U S	1,053.00	1.62 %
Neuroscience U S	997.00	1.53 %
Neuroscience Outside U S	394.00	0.6 %
Other U S	304.00	0.47 %
Other Outside U S	639.00	0.98 %
Europe	11,558.00	17.73 %
China	1,951.00	2.99 %
Japan	2,132.00	3.27 %
Rest of world	6,057.00	9.29 %
Reportable Segment	65,179.00	100 %
Total	65,179.00	100 %

Twelve months ended 2025
LLY s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Reportable Segment	20,640.00	31.67 %
Total	20,640.00	31.67 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
Net product revenue	49.6 %	-
Collaboration and other revenue	-1.72 %	-
U S Sales returns rebates and discounts	-66.67 %	-
U S	43.15 %	-
Outside U S	47.93 %	-
Cardiometabolic Health U S	54.98 %	-
Cardiometabolic Health Outside U S	87.16 %	-
Mounjaro U S	52.53 %	-
Mounjaro Outside U S	259.65 %	-
Zepbound U S	173.73 %	-
Jardiance	2.72 %	-
Jardiance U S	-1 %	-
Jardiance Outside U S	6.08 %	-
Trulicity U S	-21.12 %	-
Trulicity Outside U S	-12.69 %	-
Other cardiometabolic health U S	-16.74 %	-
Other cardiometabolic health Outside U S	-0.28 %	-
Oncology U S	6.27 %	-
Oncology Outside U S	8.26 %	-
Verzenio U S	1.26 %	-
Verzenio Outside U S	19.78 %	-
Other oncology U S	16.9 %	-
Other oncology Outside U S	-3.6 %	-
Immunology U S	20.59 %	-
Immunology Outside U S	17.98 %	-
Taltz U S	8.41 %	-
Taltz Outside U S	11.01 %	-
Other immunology U S	106.21 %	-
Other immunology Outside U S	27.33 %	-
Neuroscience U S	27.82 %	-
Neuroscience Outside U S	-43.23 %	-
Other U S	21.12 %	-
Other Outside U S	-1.99 %	-
Europe	67 %	-
China	17.53 %	-
Japan	17.47 %	-
Rest of world	41.82 %	-
Reportable Segment	44.7 %	94.9 %
Total	44.7 %	94.9 %
Humalog U S	-	-
Humalog Outside U S	-	-
Humulin U S	-	-
Humulin Outside U S	-	-
Basaglar	-	-
Basaglar U S	-	-
Basaglar Outside U S	-	-
Baqsimi U S	-	-
Baqsimi Outside U S	-	-
Cyramza U S	-	-
Cyramza Outside U S	-	-
Erbitux U S	-	-
Erbitux Outside U S	-	-
Tyvyt	-	-
Tyvyt Outside U S	-	-
Olumiant	-	-
Olumiant U S	-	-
Olumiant Outside U S	-	-
Emgality U S	-	-
Emgality Outside U S	-	-
Zyprexa U S	-	-
Zyprexa Outside U S	-	-
Other neuroscience U S	-	-
Other neuroscience Outside U S	-	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.